I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology EHA 2023
Roche and Genentech at

EHA 2023

June 08 - June 11
Frankfurt, Germany / Virtual (Hybrid)
ehaweb.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jun 28 / Roche
Watch Practical aspects of patient management in DLBCL: how can we work together to improve patient care?
Our expert panel, chaired by Prof. Christian Reinhardt, will discuss the evolving treatment landscape and decision-making process in DLBCL, and how we can overcome the day-to-day challenges that practicing hematologists and their patients may face. This session will have a strong focus on the practical aspects of patient management. This content is intended for HCPs who have attended the symposium.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 28 / Roche
Watch How can durable remissions be achieved in patients with relapsed/refractory DLBCL?
Our expert panel, chaired by Prof. Christian Reinhardt, will discuss the evolving treatment landscape and decision-making process in DLBCL, and how we can overcome the day-to-day challenges that practicing hematologists and their patients may face. This session will have a strong focus on the practical aspects of patient management. This content is intended for HCPs who have attended the symposium.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 28 / Roche
Watch How should we treat DLBCL in the first-line setting?
Our expert panel, chaired by Prof. Christian Reinhardt, will discuss the evolving treatment landscape and decision-making process in DLBCL, and how we can overcome the day-to-day challenges that practicing hematologists and their patients may face. This session will have a strong focus on the practical aspects of patient management. This content is intended for HCPs who have attended the symposium.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 28 / Roche
Watch Introduction
Our expert panel, chaired by Prof. Christian Reinhardt, will discuss the evolving treatment landscape and decision-making process in DLBCL, and how we can overcome the day-to-day challenges that practicing hematologists and their patients may face. This session will have a strong focus on the practical aspects of patient management. This content is intended for HCPs who have attended the symposium.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 22 / Roche
Paroxysmal nocturnal hemoglobinuria (PNH) outcomes and recent therapeutic developments in complement inhibition - Next-generation complement inhibition: Addressing treatment burden - Dr Jens Panse
Join a panel of PNH experts, as well as a person with PNH, as we explore the current progress and clinical research in PNH treatment.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 22 / Roche
Paroxysmal nocturnal hemoglobinuria (PNH) outcomes and recent therapeutic developments in complement inhibition - Global disparity in the burden of PNH and its treatment outcomes - Dr Talha Munir
Join a panel of PNH experts, as well as a person with PNH, as we explore the current progress and clinical research in PNH treatment.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 22 / Roche
Paroxysmal nocturnal hemoglobinuria (PNH) outcomes and recent therapeutic developments in complement inhibition - Living with PNH: Experiences with and without C5 inhibitors - Ms Olena Wagner
Join a panel of PNH experts, as well as a person with PNH, as we explore the current progress and clinical research in PNH treatment.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 22 / Roche
Paroxysmal nocturnal hemoglobinuria (PNH) outcomes and recent therapeutic developments in complement inhibition - Updates in terminal complement inhibition for previously untreated patients - Prof Dr Alexander Röth
Join a panel of PNH experts, as well as a person with PNH, as we explore the current progress and clinical research in PNH treatment.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 11 / Roche and Genentech
Final 7-year follow up and retreatment substudy analysis of MURANO: venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)
MURANO (NCT02005471) is a global, phase III, open-label, randomized study evaluating VenR vs BR in patients with R/R CLL. The final analyses of MURANO at 7 years' median follow-up are presented, including updated PFS and OS, impact of MRD status on long-term outcomes and information on TTNT. Outcomes from the substudy analyses are also reported, where patients with PD received VenR as retreatment or as crossover from BR, to assess whether VenR retreatment is a viable option.
Haematology Chronic Lymphoblastic Leukaemia EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 10 / Roche
Paroxysmal Nocturnal Hemoglobinuria (PNH) Outcomes and Recent Therapeutic Developments in Complement Inhibition
Join a panel of PNH experts, as well as a person with PNH, as we explore the current progress and clinical research in PNH treatment.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
Six-Month Crovalimab▼ Extension in the Phase III COMMODORE 3 Study: Updated Efficacy and Safety Results in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria
COMMODORE 3 is a Phase III, multicenter, single-arm trial evaluating crovalimab▼ in C5 inhibitor-naive patients with PNH in China. This presentation reports updated efficacy and safety data with an additional 6 months of crovalimab▼ exposure.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB▼ VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
COMMODORE 1 is a Phase III, global, randomized, multicenter, open-label trial evaluating crovalimab▼ in C5 inhibitor-experienced patients with PNH. This presentation reports safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy results of crovalimab▼ vs eculizumab during the 24-week primary treatment period.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
Clinical, Humanistic, and Economic Burden in Patients with PNH receiving C5 Inhibition Treatment Across UK, Germany, and France. Insights from the COMMODORE Burden of Illness Study
The COMMODORE Burden of Illness study aims to quantify the real-life clinical, humanistic, and economic burden in patients with PNH receiving C5 inhibition treatment across UK, Germany, and France. This presentation reports results from the first phase of the study.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
Tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma (RRMM) who receive cevostamab
This study was designed to assess whether a single dose of tocilizumab given prior to the initiation of cevostamab could reduce the incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma receiving cevostamab monotherapy in the Phase I GO39775 study (NCT03275103).
Haematology Multiple Myeloma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
Mosunetuzumab▼ demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: updated analysis of a pivotal Phase II study
This poster reports updated efficacy results (median follow-up 28.3 months) from an ongoing pivotal Phase II study (NCT02500407; GO29781) assessing fixed-duration mosunetuzumab▼ in patients with relapsed/refractory follicular lymphoma and ≥2 prior lines of therapy who achieved a complete response by the end-of-treatment.
Haematology Follicular Lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
An automated quantification algorithm for evaluating total metabolic tumor volume in patients with FDG-avid lymphomas using a deep learning model
This study evaluated the performance of a model to automate the detection and segmentation of lesions and TMTV quantification in patients with DLBCL or FL. The results showed good performance and acceptable levels of bias for quantification of TMTV when using DLBCL or FL data and suggest that with further optimization and validation, the model may provide a novel automated approach for lesion segmentation and TMTV quantification.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB▼ VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
COMMODORE 2 is a Phase III, global, randomized, multicenter, open-label trial evaluating crovalimab▼ in C5 inhibitor-naive patients with PNH. This presentation reports the efficacy, safety pharmacokinetics and pharmacodynamics of crovalimab▼ vs eculizumab during the 24-week primary treatment period.
Haematology Paroxysmal Nocturnal Hemoglobinuria EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 9 / Roche and Genentech
Glofitamab▼ monotherapy in patients with relapsed/refractory (R/R) large b-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study
This pivotal Phase II study (NCT03075696) was designed to evaluate glofitamab▼ monotherapy in patients with relapsed/refractory large B-cell lymphoma and ≥2 prior therapies. In this encore poster, extended follow-up and landmark analyses in patients who achieved a complete response after receiving glofitamab▼ monotherapy are reported.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 8 / Roche
Diffuse large B-cell lymphoma treatment in the modern era: decision-making and practical management
Our expert panel, chaired by Prof. Christian Reinhardt, will discuss the evolving treatment landscape and decision-making process in DLBCL, and how we can overcome the day-to-day challenges that practicing hematologists and their patients may face. This session will have a strong focus on the practical aspects of patient management, and will include a live panel discussion. This content is intended for HCPs who have attended the symposium.
Haematology Oncology Diffuse large B cell lymphoma EHA-2023
02:45 PM
Duration 5mins Frankfurt, Germany / Virtual (Hybrid)
Diffuse large B-cell lymphoma treatment in the modern era: decision-making and practical management
Reinhardt C, Osborne W, Hutchings M, Jäger U
Haematology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:45 PM
Duration 15mins Panorama 1
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomised CLL14 study
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink A, Tausch E, Schneider C, Ritgen M, Kreuzer K, Sivcheva L, Niemann C, Schwarer A, Pueyo JL, Weinkove R, Strumberg D, Kilfoyle A, Runkel E, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K
Haematology | Chronic Lymphoblastic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 15mins Illusion
THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
Röth A, He G, Brodsky A, Chai-Adisaksopha C, Dumagay T, Demichelis Gómez MR, Höglund M, Kelly R, Lee J-H, Nishimura J-I, Obara N, Risitano A, Gaya Valls A, Appius A, Gentile B, Negricea R, Zhang Z, Buatois S, Han B.
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 15mins Illusion
PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Scheinberg, P, Villa Cle D, Edwards J, Giai V, Hus M, Kim JS, Barrebetxea Lekue C, Nagy Z, Nur E, Pans JP, Ueda Y, Yenerel MN, Appius A, Balachandran N, Chebon S, Gentile B, Buatois S, Kulasekararaj A
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 PM
Duration 5mins Frankfurt, Germany / Virtual (Hybrid)
Paroxysmal nocturnal hemoglobinuria (PNH) outcomes and recent therapeutic developments in complement inhibition
Roth A, Munir T, Wagner O, Panse J
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:45 AM
Duration 15mins FestHalle
Final 7-year follow up and retreatment substudy analysis of MURANO: venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)
Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline, S, Lamanna N, Robak T, De la Serna, J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Thadani-Mulero M, Lefebure M, Jiang Y, Millen R, Boyer M, Seymour JF
Haematology | Chronic Lymphoblastic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.